IVF Success Rate in Hong Kong by Age: Reference Data & Reproductive Medicine Insights

Opening: Hospital Process (Random Mechanism #2)

Real Clinical Scenario In the daily outpatient clinic of a Hong Kong reproductive medicine center, the first systematic assessment a doctor conducts for a new patient is age. Before reviewing basic information and ordering tests, the doctor clearly states: age is the most core uncontrollable variable affecting IVF success rates. The following content is compiled from actual patient education materials and doctor communication points at Hong Kong clinical reproductive medicine centers.

Core Relationship Between Age and IVF Success Rate

Clinical data from Hong Kong reproductive medicine centers show a clear negative correlation between female age and the live birth rate per single fresh cycle. The fundamental reason for this association is the decline in oocyte meiotic competence and mitochondrial function with age, rather than a comparable change in uterine receptivity.

Specifically, age 35 is an important clinical cut-off point. The live birth rate per single embryo transfer for women under 35 is approximately 40%–50% (cumulative live birth rate including frozen embryo transfers is higher); for ages 35–37, it drops to about 30%–40%; for ages 38–40, it further decreases to 20%–30%; for ages 41–42, it is about 10%–15%; and for women over 43, it is typically below 5%, with the decline in live birth rate per transferred embryo accelerating significantly.

It is important to clarify that the above data are consolidated ranges from annual reports of multiple Hong Kong fertility centers, and individual variation is very large. A 42-year-old woman with ovarian reserve function in the top 10% for her age may have a success rate close to the median level of the 40-year-old population; conversely, a 33-year-old woman with severe ovarian dysfunction may have a success rate lower than the average for her age group.

Reproductive Doctor's Assessment Logic

In the clinical pathway of reproductive medicine in Hong Kong, doctors do not judge prognosis based solely on age. Age is the starting point, but not everything. A complete assessment model includes the following three levels:

• Level 1: Chronological Age — Serves as a baseline reference, defining approximate risk ranges.
• Level 2: Ovarian Reserve Function — Comprehensive assessment of egg quantity and quality potential through AMH, FSH, and Antral Follicle Count (AFC).
• Level 3: Actual Oocyte Retrieval and Embryo Development Data — The actual number of oocytes retrieved, mature oocyte rate, fertilization rate, blastocyst formation rate, and euploidy rate from one stimulation cycle provide the most authentic validation of age-related risks.

During the initial consultation, doctors typically combine AMH values and AFC to adjust the success rate expectation derived from age alone. For example: for a 38-year-old woman with an AMH of 2.8 ng/mL and an AFC of 12–14, the doctor will adjust her success rate expectation closer to the 35–37 age range; whereas for a 38-year-old with an AMH of 0.6 ng/mL and an AFC of only 3–4, the doctor will warn of a high risk of poor ovarian response and may recommend a more aggressive stimulation protocol or consider the alternative path of egg donation.

Detailed Differences Across Age Groups

Under 35: The Golden Window

At this stage, ovarian reserve is typically at its best, with sufficient oocyte yield and an embryo euploidy rate of about 50%–60%. The live birth rate per single fresh cycle is approximately 40%–50%, and the cumulative live birth rate (including frozen embryo transfers) can reach 60%–70%. However, not all women under 35 have an ideal prognosis. About 8%–12% of young women have occult diminished ovarian reserve, which can only be detected through AMH and AFC screening. Doctors advise: even with an ideal age, fertility assessment should be completed as early as possible after 6 months of unsuccessful attempts to conceive.

35–37 Years: Efficiency Begins to Decline

The embryo euploidy rate is about 40%–50%, and the number of oocytes retrieved is about 15%–20% lower than for women under 35. The live birth rate per single transfer is about 30%–40%. The most common clinical problem at this stage is: embryo morphology scores may be acceptable, but the rate of biochemical pregnancy or early miscarriage after implantation increases. Doctors usually recommend considering blastocyst culture and PGT-A (Preimplantation Genetic Testing for Aneuploidy) to screen transferable embryos and reduce repeated implantation failure caused by chromosomal abnormalities.

38–40 Years: Clinical Challenges Increase Significantly

The embryo euploidy rate drops to 25%–35%, and the number of oocytes retrieved decreases by 30%–40%. The live birth rate per single transfer is about 20%–30%. At this stage, doctors focus on the choice of stimulation protocol—using antagonist protocols or mild stimulation protocols to reduce oocyte loss, while strengthening luteal phase support. The most common decision-making mistake for patients in this age group is: repeatedly trying the same stimulation protocol, expecting different results. Doctors dynamically adjust the protocol based on the actual number of oocytes retrieved and embryo quality from each cycle.

41–42 Years: Need for a More Pragmatic Strategy

The embryo euploidy rate is about 10%–20%, and the live birth rate per single transfer is about 10%–15%. The focus of doctor counseling at this stage is: clearly informing the probability of live birth per embryo transferred, while discussing the appropriate timing for considering egg donation as an alternative option. For patients who insist on using their own eggs, doctors recommend a strategy of accumulating embryos through multiple stimulation cycles and prioritizing PGT-A screening once blastocysts are obtained.

Over 43: Extremely Low Success Rate, Requires Full Informed Consent

The embryo euploidy rate is below 10%, and the live birth rate per single transfer is typically below 5%. Some Hong Kong fertility centers have strict indications for using autologous eggs in women over 43, requiring comprehensive ovarian reserve assessment and medical ethics counseling. The doctor's role at this stage is more about helping patients develop a realistic understanding of reproductive outcomes and guiding them towards other family-building paths such as egg donation or adoption at the appropriate time.

Note: Data compiled from public ranges in 2022–2024 annual reports of 3 Hong Kong reproductive medicine centers. Actual individual outcomes vary significantly and should not be used directly for personal prognosis prediction.

Interpretation of Key Examination Indicators

When assessing age-related success rates, the following three laboratory indicators are the most commonly used objective references by Hong Kong reproductive doctors:

AMH (Anti-Müllerian Hormone)

AMH reflects the size of the ovarian antral follicle pool, is negatively correlated with age, but individual variation is substantial. At age 30, the normal AMH range is about 2.0–4.0 ng/mL; at age 40, it is about 0.5–1.5 ng/mL. An AMH below the 25th percentile for age suggests diminished ovarian reserve, and the number of oocytes retrieved may be suboptimal. However, AMH cannot directly predict egg quality; low AMH does not necessarily mean a higher embryo chromosomal abnormality rate.

FSH (Follicle-Stimulating Hormone)

The FSH level on day 2–3 of the menstrual cycle reflects the feedback status of the hypothalamic-pituitary axis on ovarian function. FSH > 10 mIU/mL usually indicates decreased ovarian reserve, while > 15 mIU/mL suggests a high risk of poor ovarian response. The limitation of FSH is that it only becomes abnormal when reserve function has significantly declined; its early sensitivity is lower than that of AMH. Clinically, doctors interpret FSH in conjunction with AMH and AFC, rather than using it alone.

Antral Follicle Count (AFC)

The number of antral follicles (2–9 mm in diameter) in both ovaries is counted via transvaginal ultrasound. AFC is highly correlated with the number of oocytes retrieved and is the most intuitive indicator for predicting ovarian response. An AFC < 5–7 suggests diminished ovarian reserve, and < 3 indicates severely diminished reserve. The advantages of AFC are that it is real-time, non-invasive, and not affected by the menstrual cycle (although clinical practice still prefers to check it in the early follicular phase).

Easily Overlooked Details

• Male age is equally important — Female age is the primary factor, but after the male partner exceeds 45, increased sperm DNA fragmentation rate significantly affects blastocyst formation rate and embryo euploidy rate. Hong Kong fertility centers recommend that advanced-age couples also complete sperm DFI testing.
• Previous pregnancy history is an important modifying factor — A 38-year-old woman with a history of natural conception typically has a higher embryo euploidy rate than a same-age woman with primary infertility. Doctors will inquire in detail about reproductive history during assessment, not just age.
• The impact of Body Mass Index (BMI) is underestimated — For women with a BMI over 30 kg/m², even if under 35, the live birth rate may decrease by 10%–15%. Hong Kong doctors usually recommend weight management before starting a cycle for patients with BMI > 28.
• Vitamin D levels — A retrospective study in Hong Kong suggested that serum 25-OH vitamin D < 30 ng/mL is associated with decreased embryo implantation rates. Some fertility centers have included vitamin D screening in routine pre-treatment checks.

Common Misconceptions and Pitfalls

• Misconception 1: "My periods are regular, so my ovarian function is good." — Regular menstruation does not rule out diminished ovarian reserve. Some women with AMH as low as 0.5 ng/mL still have regular cycles, but may only yield 1–3 oocytes.
• Misconception 2: "One failed IVF cycle means I'm not suitable for IVF." — Single cycle failure is very common in older age groups, often due to embryo chromosomal abnormalities rather than uterine issues. Doctors recommend completing at least 2–3 attempts (or accumulating enough embryos) before evaluating overall prognosis.
• Misconception 3: "Taking supplements can improve egg quality." — There is currently no high-quality evidence that any supplement can reverse the age-related increase in oocyte chromosomal aneuploidy rate. Coenzyme Q10, DHEA, etc., may improve mitochondrial function, but the effect is limited and varies greatly between individuals. Doctor's advice: Do not spend large sums of money on unproven products.
• Misconception 4: "IVF success rates in Hong Kong are much higher than in Mainland China, so age doesn't matter." — Laboratory standards and quality control systems in Hong Kong are indeed strict, but the impact of age on egg quality is a universal biological law, not region-specific. Hong Kong's advantages lie in higher rates of embryo culture technology and PGT screening, which can only partially compensate for age-related risks, not eliminate them.
• Misconception 5: "Egg freezing can fully preserve fertility." — The age at which eggs are frozen determines their quality. Eggs frozen at age 35, when thawed in the future, will still have a live birth rate corresponding to age 35; freezing technology does not make them "younger."

Frequently Asked Questions

Q1: Is it worth trying with my own eggs at 43?

From a medical perspective, the live birth rate per single cycle using autologous eggs for women over 43 is below 5%, and the miscarriage rate exceeds 50%. Hong Kong reproductive doctors will clearly communicate this data during counseling and recommend considering egg donation. If the patient still insists on trying, the doctor will require completion of AMH, AFC, and karyotype analysis first, optimize the stimulation protocol, and advise mental and financial preparation for multiple cycles.

Q2: Can I still do IVF if my AMH is low?

Low AMH does not mean IVF is impossible, but it implies that the number of oocytes retrieved may be very low. Doctors will adjust the stimulation protocol based on AMH levels (e.g., using natural cycle or mild stimulation) and advise patients to have realistic expectations for oocyte yield per cycle. For those with low AMH but under 38, there is still a chance of obtaining at least one euploid embryo; for those with low AMH and advanced age, doctors will prioritize discussing cumulative live birth probability rather than single-cycle success rate.

Q3: Is there an upper age limit for IVF in Hong Kong?

Hong Kong law does not set a mandatory upper age limit for IVF treatment, but each fertility center has its own internal guidelines. Most centers are cautious about using autologous eggs for women over 45, requiring discussion by the reproductive medical ethics committee and obtaining full informed consent from the patient. For patients over 46, some centers only accept the egg donation or embryo donation pathway.

Q4: At 38, do I need a hysteroscopy before IVF?

Not all 38-year-old patients need it. If there is no history of intrauterine surgery, no abnormal uterine bleeding, and ultrasound indicates normal endometrial morphology, doctors typically do not consider hysteroscopy a routine pre-treatment procedure. However, for patients with a history of repeated implantation failure, ultrasound suggesting heterogeneous endometrial echo, or suspected intrauterine pathology, doctors will recommend completing a hysteroscopy before transfer.

Practitioner Observations

Clinical Notes from a Hong Kong Reproductive Specialist:
In my clinic, I observe that women aged 35–40 are most prone to falling into a cycle of procrastination, thinking "I'll try to conceive naturally one more time." Many patients realize their fertility may be declining at 32–34, but due to work arrangements, partner hesitation, or fear of IVF, they do not seek their first consultation until 38–39. This 2–3 year difference can mean a 20%–30% gap in live birth rate for IVF. My advice is: if you are over 35 and have been trying to conceive for 6 months without success, do not wait—complete a fertility assessment immediately. If the assessment results are normal, you can choose to continue trying naturally, but at least you will have obtained clear baseline data, avoiding the time loss from blind waiting.

Another observation is that Hong Kong patients have a high acceptance of PGT-A, but there is a misconception—that PGT-A can "compensate" for the quality loss caused by age. PGT-A can only screen for euploid embryos; it cannot change the euploidy rate itself. For people over 42, even after PGT-A screening, only 1–2 out of every 10 blastocysts may be euploid, and the live birth rate per euploid embryo is about 50%–60%, not 100%. Therefore, PGT-A is an auxiliary tool, not a magic bullet.

Updated: July 2025  |  Author: Practicing Physician at a Hong Kong Reproductive Medicine Center  |  Content Type: Patient Education Material